Interview with JongHyun Park, Head of the Global Research Center at JNPMEDI
▲ JongHyun Park, Head of the Global Research Center at JNPMEDI, had an interview with our publication at Seodaemun-gu, Seoul. He emphasized, “JNPMEDI will establish itself as a Korean Systems Engineering and Technical Assistance (SETA).” Reporter TaeHyun Shin, holjjak@
JNPMEDI, a consulting firm specializing in new drug and medical device development, is expanding its business scope by providing total solutions to support the success of government-led healthcare innovation initiatives.
In a recent interview with our publication, JongHyun Park, Head of the Global Research Center at JNPMEDI, emphasized the importance of public-private collaboration in developing and commercializing innovative technologies. He stated that JNPMEDI aims to establish itself as a Korean Systems Engineering and Technical Assistance (SETA).
SETA refers to specialized advisory and support organizations that assist government agencies, such as the U.S. Defense Advanced Research Projects Agency (DARPA), by providing scientific and technical consulting, R&D support, and project management services. With SETA’s assistance, DARPA successfully executed national security-driven healthcare projects, including the development of COVID-19 vaccines during the pandemic.
“Government project managers (PMs) can focus on critical tasks by delegating areas outside their expertise to SETA and other specialized institutions,” Park explained. “SETA’s accumulated expertise and continuous support ensure project continuity, even as priorities evolve.”
▲ JongHyun Park, Head of the Global Research Center at JNPMEDI stated, “Moving forward, JNPMEDI will focus on establishing a Korean SETA while actively supporting domestic companies in expanding globally.” Reporter TaeHyun Shin
In response to the COVID-19 pandemic, the United States launched the Advanced Research Projects Agency for Health (ARPA-H) in 2022, a specialized agency dedicated to advancing healthcare innovation.
Following this model, Korea established the K-Health Future Initiative last year, aiming to drive national healthcare R&D projects that fundamentally enhance public health and welfare. The initiative is built around five key missions: △strengthening health security, △tackling intractable diseases, △securing a competitive edge in biohealth technologies, △innovating essential medical services, and △improving welfare and caregiving systems.
Park, highlighted the need for public-private collaboration to ensure that K-Health Future Initiative projects go beyond research and successfully transition into commercialization. Under this model, the government would focus on evaluating and selecting participating companies, while a Korean Systems Engineering and Technical Assistance (SETA) entity would support efficient project management, feasibility assessments, and global expansion strategies.
For instance, if JNPMEDI were to collaborate as a Korean SETA on a rare disease drug development project, its role would include conducting research to assess business viability, providing clinical strategy insights through its pharmaceutical and medical networks, and guiding commercialization efforts.
“The government serves as the filter, identifying promising projects and assessing their feasibility, while we take the next step in refining and executing them,” Park stated. “With expertise in technology commercialization, project management, and AI-driven solutions, combined with deep industry knowledge in pharmaceuticals and biotechnology, JNPMEDI is well-positioned to provide a comprehensive solution.”
▲ JongHyun Park, Head of the Global Research Center at JNPMEDI, having an interview with our publication at Seodaemun-gu, Seoul. Reporter TaeHyun Shin
Starting as a provider of solutions for contract research organizations (CROs), JNPMEDI has grown into a specialized consulting firm that oversees the entire process from preclinical development to global regulatory approval and commercialization.
The company has gained strong recognition in the innovative medical device sector, surpassing KRW 30 billion in project orders last year, with actual revenue growing 500% year-over-year. To further expand its business and network, JNPMEDI is also considering establishing a U.S. subsidiary this year.
“Our pricing is about 20% more competitive than major domestic CROs, but what truly sets us apart is our proprietary data management solutions and extensive industry network, delivering value beyond just cost savings,” said JongHyun Park, Head of the Global Research Center at JNPMEDI. He continued, “Moving forward, JNPMEDI plans to expand its Korean SETA initiative while actively supporting domestic companies in their global expansion efforts.”
📌 To see the originical article : https://www.etoday.co.kr/news/view/2457182
Interview with JongHyun Park, Head of the Global Research Center at JNPMEDI
▲ JongHyun Park, Head of the Global Research Center at JNPMEDI, had an interview with our publication at Seodaemun-gu, Seoul. He emphasized, “JNPMEDI will establish itself as a Korean Systems Engineering and Technical Assistance (SETA).” Reporter TaeHyun Shin, holjjak@
JNPMEDI, a consulting firm specializing in new drug and medical device development, is expanding its business scope by providing total solutions to support the success of government-led healthcare innovation initiatives.
In a recent interview with our publication, JongHyun Park, Head of the Global Research Center at JNPMEDI, emphasized the importance of public-private collaboration in developing and commercializing innovative technologies. He stated that JNPMEDI aims to establish itself as a Korean Systems Engineering and Technical Assistance (SETA).
SETA refers to specialized advisory and support organizations that assist government agencies, such as the U.S. Defense Advanced Research Projects Agency (DARPA), by providing scientific and technical consulting, R&D support, and project management services. With SETA’s assistance, DARPA successfully executed national security-driven healthcare projects, including the development of COVID-19 vaccines during the pandemic.
“Government project managers (PMs) can focus on critical tasks by delegating areas outside their expertise to SETA and other specialized institutions,” Park explained. “SETA’s accumulated expertise and continuous support ensure project continuity, even as priorities evolve.”
▲ JongHyun Park, Head of the Global Research Center at JNPMEDI stated, “Moving forward, JNPMEDI will focus on establishing a Korean SETA while actively supporting domestic companies in expanding globally.” Reporter TaeHyun Shin
In response to the COVID-19 pandemic, the United States launched the Advanced Research Projects Agency for Health (ARPA-H) in 2022, a specialized agency dedicated to advancing healthcare innovation.
Following this model, Korea established the K-Health Future Initiative last year, aiming to drive national healthcare R&D projects that fundamentally enhance public health and welfare. The initiative is built around five key missions: △strengthening health security, △tackling intractable diseases, △securing a competitive edge in biohealth technologies, △innovating essential medical services, and △improving welfare and caregiving systems.
Park, highlighted the need for public-private collaboration to ensure that K-Health Future Initiative projects go beyond research and successfully transition into commercialization. Under this model, the government would focus on evaluating and selecting participating companies, while a Korean Systems Engineering and Technical Assistance (SETA) entity would support efficient project management, feasibility assessments, and global expansion strategies.
For instance, if JNPMEDI were to collaborate as a Korean SETA on a rare disease drug development project, its role would include conducting research to assess business viability, providing clinical strategy insights through its pharmaceutical and medical networks, and guiding commercialization efforts.
“The government serves as the filter, identifying promising projects and assessing their feasibility, while we take the next step in refining and executing them,” Park stated. “With expertise in technology commercialization, project management, and AI-driven solutions, combined with deep industry knowledge in pharmaceuticals and biotechnology, JNPMEDI is well-positioned to provide a comprehensive solution.”
▲ JongHyun Park, Head of the Global Research Center at JNPMEDI, having an interview with our publication at Seodaemun-gu, Seoul. Reporter TaeHyun Shin
Starting as a provider of solutions for contract research organizations (CROs), JNPMEDI has grown into a specialized consulting firm that oversees the entire process from preclinical development to global regulatory approval and commercialization.
The company has gained strong recognition in the innovative medical device sector, surpassing KRW 30 billion in project orders last year, with actual revenue growing 500% year-over-year. To further expand its business and network, JNPMEDI is also considering establishing a U.S. subsidiary this year.
“Our pricing is about 20% more competitive than major domestic CROs, but what truly sets us apart is our proprietary data management solutions and extensive industry network, delivering value beyond just cost savings,” said JongHyun Park, Head of the Global Research Center at JNPMEDI. He continued, “Moving forward, JNPMEDI plans to expand its Korean SETA initiative while actively supporting domestic companies in their global expansion efforts.”
📌 To see the originical article : https://www.etoday.co.kr/news/view/2457182